Illumina ILMN Core Illumina — R&D

Similar metrics at other companies

RMDResidential Care Software — R&D

$26.23M+5.3%

BLCOVision Care — R&D

$17M+54.5%

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

INSMOther external R&D expenses — R&D

$48.84M+71.7%

FAQ

What is Illumina's core illumina — R&D?

Illumina (ILMN) reported core illumina — R&D of $240M in Q1 2026.

How has Illumina's core illumina — R&D changed year-over-year?

Illumina's core illumina — R&D decreased by 4.8% year-over-year, from $252M to $240M.

What is the long-term trend for Illumina's core illumina — R&D?

Over 3 years (2022 to 2025), Illumina's core illumina — R&D has grown at a -1.2% compound annual growth rate (CAGR), from $1B to $967M.

What does core illumina — R&D mean?

Captures the investment in innovation, including the development of new sequencing platforms, software enhancements, and clinical applications. This reflects the company's commitment to maintaining its technological lead in the genomics market.